Clinical trials
Observational Diabetes Mellitus, Type 2 trials in Finland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
19 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 12 |
| Unknown status | 4 |
| Enrolling by invitation | 1 |
| Recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novo Nordisk A/S | 5 |
| AstraZeneca | 2 |
| Boehringer Ingelheim | 2 |
| Helsinki University Central Hospital | 2 |
| Tampere University Hospital | 2 |
| Folkhälsan Researech Center | 1 |
| Markus Perola | 1 |
| National Human Genome Research Institute (NHGRI) | 1 |
| Newcastle University | 1 |
| Turku University Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 19 |
| Diabetes Mellitus | 5 |
| Diabetes Mellitus, Type 1 | 3 |
| Obesity | 3 |
| Cardiovascular Diseases | 2 |
| Liver Cirrhosis | 2 |
| Non-alcoholic Fatty Liver Disease | 2 |
| Carcinoma, Hepatocellular | 1 |
| Cognitive Dysfunction | 1 |
| Coronary Disease | 1 |
Trials
Showing 1 to 19 of 19. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.